trending Market Intelligence /marketintelligence/en/news-insights/trending/2zm4jvxxxzc1jq651ic0ag2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biohaven migraine drug cures pain, bothersome symptoms in late-stage studies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biohaven migraine drug cures pain, bothersome symptoms in late-stage studies

Biohaven Pharmaceutical Holding Co. Ltd.'s anti-migraine drug rimegepant met the main goals in two late-stage clinical trials.

The medicine was better than placebo at getting rid of pain and "most bothersome" migraine-associated symptoms in patients two hours after taking the first dose, results from the two studies, dubbed BHV3000-301 and BHV3000-302, showed.

In the 301 and 302 trials, 19.2% and 19.6% of migraine patients experienced "pain freedom" two hours after taking the drug, Biohaven said. This compares with 14.2% and 12% of patients in the placebo arm experiencing pain freedom after two hours.

Patients treated with rimegepant also achieved "freedom" from symptoms such as nausea and sensitivity to light or sound two hours after taking the drug — 36.6% and 37.6% versus the placebo group's 27.2% and 25.2%.

Rimegepant was found to be safe and well-tolerated in both the trials, with a safety profile similar to placebo.

"The topline data from our two pivotal trials show that a single, oral dose of rimegepant has the potential to be an effective and safe acute treatment for migraine, addressing both pain and most bothersome symptoms without the need for repeat dosing or rescue medicines," said lad Coric, CEO of Biohaven.

The co-primary goals achieved in the phase 3 trials are in line with the guidance from the U.S. Food and Drug Administration and based on them, Biohaven plans to file for a new drug application in 2019, the New Haven, Conn.-based biopharmaceutical company said.

Migraines are neurological disorders that can cause throbbing, sometime debilitating, headaches.

Rimegepant is part of a licensing deal between Biohaven and Bristol-Myers Squibb Co. It belongs to a class of drugs known as calcitonin gene-related peptide, receptor antagonists that block a small protein found in high levels in the sensory nerves of the head and neck during migraine attacks.

Morgan Stanley's Matthew Harrison in a May 30, 2017, note had projected $150 million in sales in 2020, expecting its launch that year, and $1.4 billion peak sales by 2030 — which would make rimegepant a blockbuster.